Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FibroGen, Inc.

http://www.fibrogen.com

Latest From FibroGen, Inc.

Medicare Bundled Payment Policies Could Cut Amgen’s Parsabiv Sales By 50%

Amgen looks forward to working with CMS and Congress to shape Medicare reimbursement policies in a way that better ensures access.

Medicare Reimbursement

AZ Brushes Off Vaccine Criticism, Awaits US Readout

While fast-developing news on COVID-19 is grabbing the headlines, oncology will continue to drive growth in 2021.

Clinical Trials Commercial

Watching The Review Clock: Are US FDA Goal Date Extensions Reason For Optimism?

Novel agents that received three-month user fee goal date extensions have a slightly higher approval rate than novel applications overall.

Drug Review Approvals

China Approves Record New Cancer, Orphan Drugs In 2020 But Access Challenges Remain

Throughout 2020, China’s drive to introduce more and newer drugs to the market did not slow but was rather accelerated by the COVID-19 pandemic. But can people afford them?

Approvals Pink Sheet Perspectives
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Medical Devices
    • Biomaterials
  • Other Names / Subsidiaries
    • FibroGen China Anemia Holdings Ltd.
    • FibroGen (China) Medical Technology Development Co., Ltd.
    • FibroGen Europe Oy
    • FibroGen International (Cayman) Limited
    • FibroGen International (Hong Kong) Limited
    • Skin Sciences, Inc.
UsernamePublicRestriction

Register